Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

The long answer along with a dosage chart you can find below ... Tirzepatide, sold as Mounjaro and Zepbound, is another GLP-1 agonist and a GIP agonist, too. Its two main effects make it more ...

The Zepbound LillyDirect offers comes in a single-dose vial rather than as an auto-injector pen, also called a Zepbound pen. The vial doses available are 2.5 mg and 5 mg, which is limited compared ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

The following bupropion dosage chart highlights the basics, including the typical starting dose and the maximum or largest dose of bupropion per day. All doses are listed in milligrams (mg).

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.